Real-world dosing data for regorafenib in patients with metastatic colorectal cancer was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study.
Angelica Welch
Articles by Angelica Welch
Francisco J. Esteva, MD, PhD, discusses the current data surrounding CT-P6 demonstrating its potential as a biosimilar for trastuzumab in the United States.
Latest Updated Articles
Trastuzumab Biosimilar Candidate Shows Promise in Early-Stage Breast CancerPublished: August 31st 2018 | Updated:
Expert Discusses Real-World Data for Regorafenib in mCRCPublished: December 20th 2018 | Updated: